

Robert F Storey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5591414/robert-f-storey-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

333
papers

42,375
citations

75
h-index

204
g-index

410
ext. papers

51,456
ext. citations

7.6
avg, IF

6.8
L-index

#	Paper	IF	Citations
333	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. <i>Nature Reviews Cardiology</i> , 2022 ,	14.8	16
332	Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. <i>Platelets</i> , 2021 , 32, 555-559	3.6	2
331	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute Cardiovascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 343-355	4.3	4
330	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2021 , 143, 1215-1223	16.7	1
329	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021 , 17, 59-66	3.1	6
328	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 992-998	5.1	3
327	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , 2021 , 42, 2973-2985	9.5	10
326	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2021 , 1-7	3.6	4
325	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. <i>Haematologica</i> , 2021 , 106, 1616-1623	6.6	1
324	Novel approaches to P2Y inhibition and aspirin dosing. <i>Platelets</i> , 2021 , 32, 7-14	3.6	10
323	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 549-559	3.9	3
322	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 125-140	6.4	16
321	Antithrombotic therapy for patients with chronic coronary syndromes. <i>Heart</i> , 2021 , 107, 925-933	5.1	6
320	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021 , 143, 470-478	16.7	13
319	A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia. <i>Molecular and Cellular Proteomics</i> , 2021 , 20, 100021	7.6	4
318	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2021 , 324, 30-37	3.2	1
317	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021 , 42, 1289-1367	9.5	920

316	Ticagrelor: clinical development and future potential. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 373-394	3.9	2
315	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003006	5.2	1
314	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021 , 10, e017008	6	6
313	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021 , 42, 2235-2259	9.5	8
312	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment-Elevation Myocardial Infarction: Insights From the COMPLETE Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010458	6	0
311	Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. <i>Cardiovascular Research</i> , 2021 , 117, e123-e125	9.9	2
310	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. <i>Clinical Cardiology</i> , 2021 , 44, 1333-1343	3.3	1
309	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e020446	6	1
308	Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events. <i>European Heart Journal</i> , 2021 ,	9.5	3
307	Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. <i>BMJ, The</i> , 2021 , 374, n2106	5.9	7
306	Ticagrelor monotherapy in CKD: better safety at what price?. <i>European Heart Journal</i> , 2021 , 42, 4694-4696	5.5	2
305	The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it? 2021 , 193-199		
304	A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control.. <i>Cardiovascular Diabetology</i> , 2021 , 20, 238	8.7	1
303	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e015331	6	16
302	Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e015785	6	2
301	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
300	New Antithrombotic Drugs in Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
299	Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography Substudys. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008768	6	24

298	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 242-257	14.8	41
297	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 930-943	6.1	9
296	Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y Inhibition. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
295	The cardiac complications of COVID-19: many publications, multiple uncertainties. <i>Vascular Biology (Bristol, England)</i> , 2020 , 2, R105-R114	2.9	1
294	The cardiac complications of COVID-19: many publications, multiple uncertainties. <i>Vascular Biology (Bristol, England)</i> , 2020 , 2, R105-R114	2.9	1
293	Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. <i>Platelets</i> , 2020 , 1-6	3.6	0
292	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1125-1139	6.1	3
291	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 412-422	7	12
290	Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. <i>Platelets</i> , 2020 , 31, 945-951	3.6	3
289	Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. <i>Cardiovascular Diabetology</i> , 2020 , 19, 3	8.7	17
288	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 222-230	6.4	4
287	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2020 , 41, 1625-1632	9.5	19
286	Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. <i>European Heart Journal</i> , 2020 , 41, 483-484	9.5	2
285	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 3132-3140	9.5	24
284	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 65-74	7	7
283	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020 , 293, 35-41	3.1	2
282	Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. <i>European Heart Journal Supplements</i> , 2020 , 22, M26-M34	1.5	1
281	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020 , 5, 1255-1262	16.2	12

280	Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	4
279	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1277-1286	15.1	6
278	Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016360	6	2
277	Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 313-322	4.3	7
276	Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. <i>Platelets</i> , 2020 , 31, 174-178	3.6	13
275	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
274	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 538-564	7	39
273	Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. <i>JAMA Cardiology</i> , 2020 , 5, 881-888	16.2	34
272	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019 , 42, 1202-1209	3.3	10
271	Complete Revascularization with Multivessel PCI for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019 , 381, 1411-1421	59.2	273
270	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 563-569	5.1	6
269	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. <i>JAMA Cardiology</i> , 2019 , 4, 1092-1101	16.2	63
268	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 2402-2410	9.4	18
267	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 200-206	6.4	17
266	Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019 , 213, 57-65	4.9	6
265	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019 , 380, 1509-1524	59.2	538
264	Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1583-1589	7	5
263	Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1187-1199	5.6	38

262	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e011139	6	20
261	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , 2019 , 115, 1512-1518	9.9	9
260	Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. <i>Platelets</i> , 2019 , 30, 148-157	3.6	16
259	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019 , 30, 579-588	3.6	4
258	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European	3.9	155
257	Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available on of Randomized Trials and Meta-Analyses. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1573-1582	7	3
256	Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2019 , 215, 157-166	4.9	11
255	Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). <i>Journal of the American College of Cardiology</i> , 2019 , 74, 699-711	15.1	14
254	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1521-1537	5	189
253	Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2713-2723	15.1	43
252	Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 413-421	3.8	11
251	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 294-302	9.4	12
250	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019 , 19, 173-183	4	15
249	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, E369-E377	2.7	3
248	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 208-217	4.3	11
247	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 2048872619878075	4.3	8
246	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018 , 39, 1672-1686f	9.5	59
245	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 489-496	15.1	41

244	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 427-429	7	1
243	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , 2018 , 39, 1078-1085	9.5	73
242	The challenges of antithrombotic therapy in patients with left ventricular thrombosis. <i>European Heart Journal</i> , 2018 , 39, 209-211	9.5	2
241	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	6
240	Actualizaci3n ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboraci3n con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2018 , 71, 42.e1-42.e58	15.5	2
239	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018 , 39, e1-e33	9.5	18
238	Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 108	15.1	1
237	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2018 , 39, 213-260	9.5	1475
236	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 34-78	3	149
235	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018 , 137, 684-692	16.7	10
234	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. <i>American Heart Journal</i> , 2018 , 202, 54-60	4.9	3
233	Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1250-1256	17.56	15
232	Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). <i>Circulation</i> , 2018 ,	16.7	48
231	Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. <i>EuroIntervention</i> , 2018 , 14, 789-797	3.1	2
230	Thrombotic response 2018 , 1227-1230		2
229	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. <i>American Heart Journal</i> , 2018 , 196, 56-64	4.9	6
228	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. <i>JAMA Cardiology</i> , 2018 , 3, 1160-1166	16.2	34
227	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018 , 7, e009260	6	7

226	Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. <i>Blood Advances</i> , 2018 , 2, 715-730	7.8	24
225	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018 , 15, 480-496	14.8	134
224	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 500-510	4.3	13
223	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017 , 186, 91-99	4.9	24
222	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017 , 63, 573-584	5.5	20
221	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. <i>American Journal of Cardiology</i> , 2017 , 119, 1135-1140	3	4
220	Monitoring Antiplatelet Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2017 , 43, 311-319	5.3	24
219	Comparison of P2Y inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive 'real-world' patients. <i>Platelets</i> , 2017 , 28, 767-773	3.6	13
218	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	16
217	Platelet-related biomarkers and their response to inhibition with aspirin and p2y-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 145-153	5.1	11
216	Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. <i>International Journal of Cardiology</i> , 2017 , 244, 49-53	3.2	2
215	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017 , 40, 390-398	3.3	12
214	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017 , 136, 1955-1975	16.7	215
213	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1760-1776	15.1	100
212	The IL-1RI Co-Receptor TILRR (Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. <i>JACC Basic To Translational Science</i> , 2017 , 2, 398-414	8.7	10
211	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1455-1462	9.5	63
210	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1368-1375	15.1	50
209	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 527-538	15.1	17

208	Ticagrelor: Effects Beyond the P2Y Receptor. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 49-55	1.4	12
207	Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 573-583	2.9	4
206	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia	3.9	75
205	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1093-1100e, 2017 , 19, 1757-1758	7	6
204	72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. <i>Heart</i> , 2017 , 103, A53.2-A54	5.1	
203	B \square Arg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 295-302	7	3
202	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 940-947	7	20
201	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1710-1716	9.5	38
200	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. <i>EuroIntervention</i> , 2017 , 13, 69-77	3.1	13
199	Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017 , 55, 416-424	2	5
198	Platelets in Acute Coronary Syndromes 2017 , 1015-1028		
197	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 211-261	9.5	3850
196	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016 , 37, 1325-33	9.5	91
195	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016 , 37, 400-8	9.5	54
194	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). <i>Circulation</i> , 2016 , 134, 861-71	16.7	34
193	P2Y ₁₂ receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 369-78	7	83
192	Studies of the interaction of ticagrelor with the P2Y receptor and with P2Y-dependent pro-platelet formation by human megakaryocytes. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1079-1088	7	12
191	27 Impact of Culprit Versus Non-Culprit Angiography Strategy on Primary PCI Door to Balloon Times. <i>Heart</i> , 2016 , 102, A18-A18	5.1	

190	Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 96-102	7	45
189	The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) - a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 579	2.8	16
188	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. <i>JAMA Cardiology</i> , 2016 , 1, 425-32	16.2	70
187	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 3-12	4.3	36
186	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016 , 9, e002951	6.4	7
185	Association of MicroRNAs and YRNAs With Platelet Function. <i>Circulation Research</i> , 2016 , 118, 420-432	15.7	125
184	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016 , 25, 1447-56	5.6	32
183	Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. <i>Heart</i> , 2016 , 102, 783-9	5.1	18
182	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016 , 102, 617-25	5.1	48
181	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1145-1154	15.1	82
180	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-HII Analysis. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 646-56	5	25
179	Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. <i>Platelets</i> , 2016 , 27, 191-5	3.6	22
178	Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics. <i>International Journal of Cardiology</i> , 2016 , 202, 167-73	3.2	13
177	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016 , 37, 1133-42	9.5	103
176	Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2016 , 54, 666-74	2	16
175	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 685-711	7	21
174	Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. <i>Vascular Pharmacology</i> , 2016 , 84, 25-7	5.9	11
173	Ticagrelor: agonising over its mechanisms of action. <i>Blood</i> , 2016 , 128, 2595-2597	2.2	5

172	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2719-2728	15.1	225
171	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2732-2740	15.1	141
170	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016 , 18, 48	4.2	4
169	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016 , 177, 1-8	4.9	18
168	Cangrelor for the management and prevention of arterial thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 991-9	2.5	8
167	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129
166	Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. <i>Vascular Pharmacology</i> , 2015 , 71, 201-7	5.9	22
165	Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. <i>American Journal of Medicine</i> , 2015 , 128, 914.e11-9	2.4	8
164	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , 2015 , 372, 1791-800	59.2	1193
163	Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 2562-70	9.4	82
162	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4, e002490	6	30
161	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. <i>American Heart Journal</i> , 2015 , 169, 879-889.e7	4.9	33
160	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate Dyspnea Related to ticagrelor. <i>American Heart Journal</i> , 2015 , 170, 465-70	4.9	7
159	NLR4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATElet inhibition and patient Outcomes Trial (PLATO). <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 498-506		21
158	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 734-42	3.9	65
157	Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 555-60	4.3	33
156	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: findings from the EPICOR study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 254-62	4.3	13
155	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 37-52	7	37

154	203 Ticagrelor and Clopidogrel Attenuate the Prothrombotic State induced by Bacterial Endotoxaemia. <i>Heart</i> , 2015 , 101, A112.1-A112	5.1	
153	The role of platelets in inflammation. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 449-58	7	274
152	How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors □ is an algorithm the answer?. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 37-52	7	26
151	Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 221-30	7	28
150	Effect of P2Y12 inhibitors on inflammation and immunity. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 490-77		56
149	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. <i>European Heart Journal</i> , 2015 , 36, 1901-12	9.5	75
148	Expert position paper on air pollution and cardiovascular disease. <i>European Heart Journal</i> , 2015 , 36, 83-93	9.5	445
147	Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period. <i>Platelets</i> , 2015 , 26, 271-3	3.6	2
146	The future of P2Y12 receptor antagonists. <i>Platelets</i> , 2015 , 26, 392-8	3.6	10
145	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2015 , 66, B36	15.1	7
144	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. <i>Revista Española De Cardiología</i> , 2015 , 68, 1125.e1-1125.e64	1.5	20
143	PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. <i>Platelets</i> , 2015 , 26, 236-42	3.6	18
142	Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 516-8	15.1	1
141	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. <i>EuroIntervention</i> , 2015 , 11, 737-45	3.1	39
140	Abstract 11594: Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Circulation</i> , 2015 , 132,	16.7	2
139	Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 19-28	3.3	15
138	Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2014 , 129, 293-303	16.7	79
137	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014 , 167, 437-444.e5	4.9	74

136	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014 , 35, 2083-93	9.5	141
135	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014 , 35, 1541-50	9.5	53
134	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, <i>International</i>	3.2	8
133	Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. <i>Platelets</i> , 2014 , 25, 416-22	3.6	13
132	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014 , 100, 1762-9	5.1	34
131	Prehospital ticagrelor in ST-segment elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2014 , 371, 1016-27	59.2	409
130	Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. <i>American Heart Journal</i> , 2014 , 168, 530-6	4.9	36
129	No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, <i>International</i>	3.2	4
128	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic indication considerations. <i>Postgraduate Medical Journal</i> , 2014 , 90, 520-8 <i>Cardiology</i> , 2014 , 116, 300-2	2	21
127	Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1270-80	15.1	46
126	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular	9.5	413
125	Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1493-9 <i>Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal</i> , 2014 , 35, 3155-79	15.1	39
124	Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1048-57	15.1	38
123	Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 936-44	3	16
122	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. <i>American Heart Journal</i> , 2014 , 168, 96-102.e2	4.9	15
121	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2014 , 35, 1510-4	9.5	58
120	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 883-91	7	21
119	Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 12-4	7	4

118	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014 , 25, 517-25	3.6	115
117	Beware the normal angiogram. <i>Clinical Medicine</i> , 2014 , 14, 323-4	1.9	
116	Genetics of response to antiplatelet therapy. <i>Progress in Molecular Biology and Translational Science</i> , 2014 , 124, 123-53	4	8
115	Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". <i>Circulation</i> , 2014 , 129, e494-5	16.7	2
114	215 Ticagrelor Inhibits Release of Pro-inflammatory Cytokines TNF and IL-6 during Human Endotoxaemia. <i>Heart</i> , 2014 , 100, A117.3-A118	5.1	3
113	Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. <i>Cardiovascular Research</i> , 2014 , 102, 429-35	9.9	34
112	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2014 , 35, 209-15	9.5	190
111	Response variability to P2Y12 receptor inhibitors: expectations and reality. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 1111-28	5	104
110	Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 671-83	5	26
109	Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. <i>Circulation</i> , 2013 , 127, 673-80	16.7	58
108	Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. <i>Platelets</i> , 2013 , 24, 643-8	3.6	2
107	Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. <i>American Journal of Medicine</i> , 2013 , 126, 723-729.e1	2.4	5
106	Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. <i>Value in Health</i> , 2013 , 16, 574-80	3.3	21
105	Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATElet Inhibition and Patient Outcomes (PLATO) study. <i>Clinical Chemistry</i> , 2013 , 59, 1369-75	5.5	17
104	Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. <i>Circulation</i> , 2013 , 128, 1055-65	16.7	99
103	Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. <i>Stroke</i> , 2013 , 44, 1477-9	6.7	4
102	Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". <i>Stroke</i> , 2013 , 44, e95-6	6.7	
101	Hirudin anticoagulation allows more rapid determination of P2Y ₁₂ inhibition by the VerifyNow P2Y ₁₂ assay. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 550-5	7	9

100	Platelet function testing and prediction of procedural bleeding risk. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 817-24	7	28
99	Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 609-15	7	75
98	Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. <i>EuroIntervention</i> , 2013 , 9, 62-9	3.1	50
97	Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012 , 14, 24-38	2.1	10
96	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2012 , 366, 20-33	59.2	570
95	ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. <i>Circulation</i> , 2012 , 125, 514-21	16.7	31
94	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2012 , 164, 334-342.e1	4.9	47
93	Response to Letter Regarding Article, Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO. <i>Circulation</i> , 2012 , 126,	16.7	1
92	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 173	0.7	7
91	Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. <i>Circulation</i> , 2012 , 125, 978-86	16.7	139
90	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 173.e1-173.e55	1.5	15
89	Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 397-409	6.2	44
88	Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>American Heart Journal</i> , 2012 , 164, 728-34	4.9	8
87	Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1623-30	15.1	66
86	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1581-98	15.1	2143
85	Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 680-8	5.8	144
84	Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. <i>Circulation</i> , 2012 , 125, 2914-21	16.7	92
83	Republished education in heart: New P2Y ₁ inhibitors. <i>Postgraduate Medical Journal</i> , 2012 , 88, 49-54	2	

82	Contemporary management of ST-segment elevation myocardial infarction. <i>Hospital Practice (1995)</i> , 2012 , 40, 224-31	2.2	
81	Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. <i>Cmaj</i> , 2012 , 184, 1135-42	3.5	23
80	Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. <i>Clinical Chemistry</i> , 2012 , 58, 190-9	5.5	34
79	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 2551-67	9.5	2064
78	Development and clinical use of prasugrel and ticagrelor. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5240-50	6.0	16
77	Platelet function testing in atherothrombotic disease. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5379-91	3.3	28
76	Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 672-84	15.1	370
75	The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1988-16	15.1	101
74	Update on lipids, inflammation and atherothrombosis. <i>Thrombosis and Haemostasis</i> , 2011 , 105 Suppl 1, S34-42	7	118
73	Ticagrelor: from concept to clinical evaluation. <i>Biomarkers in Medicine</i> , 2011 , 5, 53-62	2.3	7
72	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. <i>American Heart Journal</i> , 2011 , 162, 160-5	4.9	63
71	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011 , 32, 2551-2074	9.5	2614
70	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	9.5	2020
69	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011 , 64, 1168	0.7	11
68	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , 2011 , 217 Suppl 1, S1-44	3.1	152
67	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>Atherosclerosis</i> , 2011 , 217, 3-46	3.1	459
66	Education in atherothrombosis. <i>Thrombosis and Haemostasis</i> , 2011 , 105 Suppl 1, S1-2	7	1
65	ST Elevation Acute Coronary Syndromes in PLATO. <i>Circulation</i> , 2011 , 1	16.7	

64	Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. <i>Thrombosis and Haemostasis</i> , 2011 , 105 Suppl 1, S75-81	7	29
63	Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1730-7	15.4	41
62	Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). <i>American Journal of Cardiology</i> , 2011 , 108, 1542-6	3	52
61	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011 , 32, 2922-32	9.5	160
60	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATElet inhibition and patient Outcomes (PLATO) trial. <i>BMJ, The</i> , 2011 , 342, d3527	5.9	199
59	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. <i>European Heart Journal</i> , 2011 , 32, 2945-53	9.5	136
58	Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2011 , 124, 544-54	16.7	329
57	New P2Y ₁₂ inhibitors. <i>Heart</i> , 2011 , 97, 1262-7	5.1	13
56	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011 , 32, 2933-44	9.5	262
55	Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques. <i>PLoS ONE</i> , 2010 , 5, e10130	3.7	38
54	Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 1210-7	7	69
53	Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. <i>Circulation</i> , 2010 , 121, 1188-99	16.7	372
52	First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 556-66		135
51	Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 2385-91	9.4	41
50	TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY. <i>Journal of the American College of Cardiology</i> , 2010 , 55, A108.E1007	15.1	3
49	Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 185-93	15.1	132
48	Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATElet inhibition and patient Outcomes) PLATELET substudy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1456-62	15.1	287
47	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010 , 31, 3006-16	9.5	317

46	Antiplatelet therapy and vascular disease: an update. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010 , 4, 249-75	3.4	15
45	Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. <i>Circulation</i> , 2010 , 122, 2131-41	16.7	392
44	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. <i>Lancet, The</i> , 2010 , 375, 283-93	40	531
43	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. <i>Lancet, The</i> , 2010 , 376, 1320-8	40	598
42	Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2010 , 122, 1056-67	16.7	280
41	Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. <i>Clinical Cardiology</i> , 2010 , 33, 206-12	3.3	41
40	Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. <i>Pharmacology & Therapeutics</i> , 2010 , 127, 95-107	13.9	15
39	Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. <i>Circulation</i> , 2009 , 120, 2577-85	16.7	866
38	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2	4753
37	Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. <i>Platelets</i> , 2009 , 20, 341-8	3.6	51
36	Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009 , 157, 599-605	4.9	302
35	Clopidogrel in acute coronary syndrome: to genotype or not?. <i>Lancet, The</i> , 2009 , 373, 276-8	40	22
34	The right oral antithrombotics in acute coronary syndromes. <i>Lancet, The</i> , 2009 , 374, 1947-8	40	10
33	Prasugrel 2009 , 1-4		
32	MRS 2395 2009 , 1-2		
31	Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. <i>Platelets</i> , 2008 , 19, 239-51	3.6	11
30	The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. <i>Platelets</i> , 2008 , 19, 125-33	3.6	56
29	New developments in antiplatelet therapy. <i>Country Review Ukraine</i> , 2008 , 10, D30-D37		6

28	Variability of response to antiplatelet therapy. <i>Country Review Ukraine</i> , 2008 , 10, A21-A27		11
27	Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1811-14	15.1	405
26	Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1852-6	15.1	375
25	AR-C69931MX 2007 , 1-4		
24	ARL67085 2007 , 1-3		
23	ARL66096 2007 , 1-2		
22	Biology and pharmacology of the platelet P2Y12 receptor. <i>Current Pharmaceutical Design</i> , 2006 , 12, 1255-9	3.9	148
21	Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. <i>Platelets</i> , 2006 , 17, 250-8	3.6	62
20	Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention. <i>Thrombosis and Haemostasis</i> , 2006 , 95, 997-1002	7	5
19	Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. <i>Platelets</i> , 2005 , 16, 73-80	3.6	38
18	PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. <i>Platelets</i> , 2005 , 16, 340-5	3.6	44
17	Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. <i>Platelets</i> , 2005 , 16, 398-407	3.6	38
16	Potential of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. <i>Thrombosis Research</i> , 2005 , 115, 301-7	8.2	18
15	Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. <i>Annals of Thoracic Surgery</i> , 2005 , 80, 149-52	2.7	45
14	Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. <i>Thrombosis and Haemostasis</i> , 2005 ,	7	16
13	Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. <i>Thrombosis and Haemostasis</i> , 2005 , 94, 831-8	7	95
12	Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. <i>Platelets</i> , 2004 , 15, 465-74	3.6	30
11	Anticoagulants, antiplatelets and thrombolytics. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 442-448	3.8	78

10	Clopidogrel resistance. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 63, 397-8	2.7	12
9	Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 488-494	7	132
8	Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. <i>Platelets</i> , 2002 , 13, 407-13	3.6	128
7	Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 488-94	7	43
6	Open Multicentre Study of the P2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 401-407	7	172
5	Clinical experience with antithrombotic drugs acting on purine receptor pathways. <i>Drug Development Research</i> , 2001 , 52, 202-212	5.1	2
4	Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. <i>Platelets</i> , 2001 , 12, 443-7	3.6	89
3	The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. <i>British Journal of Haematology</i> , 2000 , 110, 925-34	4.5	211
2	A Whole Blood Assay of Inhibition of Platelet Aggregation by Glycoprotein IIb/IIIa Antagonists: Comparison with other Aggregation Methodologies. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 1307-1311	7	33
1	Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease1-14		